The post AI Therapy Chatbots Face State Bans in US appeared on BitcoinEthereumNews.com. AI therapy chatbots are the target of accelerating state-level legislativeThe post AI Therapy Chatbots Face State Bans in US appeared on BitcoinEthereumNews.com. AI therapy chatbots are the target of accelerating state-level legislative

AI Therapy Chatbots Face State Bans in US

For feedback or concerns regarding this content, please contact us at [email protected]

AI therapy chatbots are the target of accelerating state-level legislative bans, with Maine sending a prohibition bill to the governor on April 10 and Missouri moving a similar measure through an omnibus health care bill.

Summary

  • Maine’s LD 2082 would prohibit clinical use of AI in mental health therapy while allowing administrative applications.
  • Missouri’s HB 2372 would ban AI from therapy, psychotherapy, and mental health diagnosis, with a $10,000 first-violation penalty.
  • The legislation reflects a growing state-level consensus that AI should not replace licensed human therapists in clinical settings.

Two US states moved this week to formally restrict or ban the clinical use of AI in mental health therapy, reflecting a surge in legislative activity targeting therapy chatbots that has picked up significant speed in 2026. The actions in Maine and Missouri are the clearest examples yet of how states are moving faster than the federal government on AI mental health regulation.

Maine’s LD 2082 was sent to the governor on April 10. The bill would prohibit the clinical use of AI in mental health therapy while allowing it in purely administrative roles. Missouri’s HB 2372 goes further, covering therapy services, psychotherapy services, and mental health diagnoses, with a $10,000 penalty for first violations enforced by the state Attorney General, according to the Transparency Coalition.

The distinction both bills draw, between clinical treatment and administrative support, reflects a legislative approach that aims to preserve AI’s efficiency benefits in healthcare while drawing a firm line against AI replacing licensed clinical judgment in therapeutic settings.

Why States Are Acting Now

The surge in state-level AI regulation is driven in part by the rapid proliferation of commercial therapy chatbot products marketed directly to consumers, some of which have been deployed in clinical or clinical-adjacent settings without the same oversight applied to human practitioners. Critics say these products have been reaching vulnerable people while regulatory frameworks remained largely silent.

As crypto.news reported, AI is now being embedded across government agencies in sensitive analytical roles, creating pressure on policymakers at every level to define where AI can and cannot substitute for human judgment. The therapy chatbot bans are a direct legislative answer to that pressure in a healthcare context.

The Broader AI Regulation Trend

The therapy chatbot bans are part of a wider legislative wave. More than 10 anti-prediction market bills have been introduced in Congress since January 2026, and state legislatures across the country have filed dozens of AI-focused measures targeting different sectors.

As crypto.news noted, the federal government is simultaneously accelerating AI adoption and fighting legal battles over where AI authority begins and ends. States appear to be filling the vacuum, passing binding restrictions on specific high-risk applications while Washington debates broader frameworks.

Source: https://crypto.news/ai-therapy-chatbots-face-state-bans-in-us/

Market Opportunity
SURGE Logo
SURGE Price(SURGE)
$0.01292
$0.01292$0.01292
+0.31%
USD
SURGE (SURGE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!